|
1）Thomas DJ, du Boulay GH, Marshall J, et al. Cerebral blood-flow in polycythaemia. Lancet. 1977; 2: 161-3
|
|
|
|
2）Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet. 1978; 2: 1219-22
|
|
|
|
|
|
3）Di Nisio M, Barbui T, Di Gennaro L, et al. The haematocrit and platelet target in polycythemia vera. Br J Haematol. 2007; 136: 249-59
|
|
|
|
|
4）Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013; 368: 22-33
|
|
|
|
|
|
5）Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013; 122(13): 2176-84
|
|
|
|
|
|
6）Wautier MP, El Nemer W, Gane P, et al. Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha 5 chain and Lu/BCAM. Blood. 2007; 110: 894-901
|
|
|
|
|
|
7）De Grandis M, Cambot M, Wautier MP, et al. JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway. Blood. 2013; 121: 658-65
|
|
|
|
|
|
8）Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995; 332: 1132-7
|
|
|
|
|
|
9）McMullin MF, Harrison CN, Kiladjian JJ. Treatment target in polycythemia vera. N Engl J Med. 2013; 368: 1554-5
|
|
|
|
|
|
10）Leone G. Treatment target in polycythemia vera. N Engl J Med. 2013; 368: 1555
|
|
|
|
|
|
11）Prchal JT, Gordeuk VR. Treatment target in polycythemia vera. N Engl J Med. 2013; 368: 1555-6
|
|
|
|
|
|
12）Marchioli R, Vannucchi AM, Barbui T. Treatment target in polycythemia vera. N Engl J Med. 2013; 18; 368: 1556
|
|
|
|
|
|
13）Kannel WB, Gordon T, Wolf PA, et al. Hemoglobin and the risk of cerebral infarction: the Framingham Study. Stroke. 1972; 3: 409-20
|
|
|
|
|